Excessive or inappropriate blood clotting leads to life-threatening vascular blockages. Preventing these events without compromising systemic hemostasis reduces mortality in thromboembolic disorders.

Inadequate immune response prevents effective targeting of pathological cells. Enhancing activation overcomes therapeutic resistance in oncology and infectious disease.

Premature release of potent cytotoxic agents causes severe damage to healthy tissues. Restricting activation to the tumor microenvironment improves the therapeutic index.